Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Diabetes Mellitus: Overview and Type I Subtype

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...

Type I Diabetes II: Pathophysiology

Type I Diabetes II: Pathophysiology

Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...

Type I Diabetes I: Introduction

Type I Diabetes I: Introduction

Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1 diabetes is an...

Insulin: Dosing Regimen and Adverse Effects

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...

Diabetes Mellitus: Type 2 and Gestational

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...

Diabetes: Management and Pharmacotherapy

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Effect of ranolazine on glycaemic control in patients with type 2 diabetes treated with either glimepiride or metformin.

Diabetes, obesity & metabolism·2016

Same author

Subcutaneous injection of hyaluronidase with recombinant human insulin compared with insulin lispro in type 1 diabetes.

Diabetes, obesity & metabolism·2014

Same author

Options for prandial glucose management in type 2 diabetes patients using basal insulin: addition of a short-acting GLP-1 analogue versus progression to basal-bolus therapy.

Diabetes, obesity & metabolism·2013

Same author

Primary and secondary prevention of Type 1 diabetes.

Diabetic medicine : a journal of the British Diabetic Association·2012

Same author

Innate and adaptive immune gene expression profiles as biomarkers in human type 1 diabetes.

Clinical and experimental immunology·2012

Same author

Glycemia and cardiovascular diseases in type 2 diabetes.

Journal of internal medicine·2010

Search research articles

Related Experiment Video

Updated: Jun 4, 2026

Bioluminescent Monitoring of Graft Survival in an Adoptive Transfer Model of Autoimmune Diabetes in Mice

Bioluminescent Monitoring of Graft Survival in an Adoptive Transfer Model of Autoimmune Diabetes in Mice

Published on: November 18, 2022

Immune intervention for type 1 diabetes mellitus.

¹Division of Endocrinology, Diabetes and Metabolism; and Diabetes Research Institute, University of Miami Miller School of Medicine, Miami, FL, USA. jskyler@miami.edu

International Journal of Clinical Practice. Supplement

|February 18, 2011

Summary

Type 1 diabetes (T1D) involves immune-mediated destruction of pancreatic beta cells. Research focuses on immune interventions to preserve beta cell function and slow T1D progression.

More Related Videos

High-Efficiency Generation of Antigen-Specific Primary Mouse Cytotoxic T Cells for Functional Testing in an Autoimmune Diabetes Model

High-Efficiency Generation of Antigen-Specific Primary Mouse Cytotoxic T Cells for Functional Testing in an Autoimmune Diabetes Model

Published on: August 16, 2019

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes

Published on: August 20, 2007

Related Experiment Videos

Last Updated: Jun 4, 2026

Bioluminescent Monitoring of Graft Survival in an Adoptive Transfer Model of Autoimmune Diabetes in Mice

Bioluminescent Monitoring of Graft Survival in an Adoptive Transfer Model of Autoimmune Diabetes in Mice

Published on: November 18, 2022

High-Efficiency Generation of Antigen-Specific Primary Mouse Cytotoxic T Cells for Functional Testing in an Autoimmune Diabetes Model

High-Efficiency Generation of Antigen-Specific Primary Mouse Cytotoxic T Cells for Functional Testing in an Autoimmune Diabetes Model

Published on: August 16, 2019

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes

Published on: August 20, 2007

Area of Science:

Immunology
Endocrinology
Pathology

Background:

Type 1 diabetes (T1D) is primarily an autoimmune disease characterized by immune-mediated destruction of pancreatic islet beta cells.
While T-lymphocytes are the primary mediators, antigen-presenting cells and B-lymphocytes also play roles in the immune response.
The disease process is insidious, with symptoms appearing only after significant beta cell loss, though some function may persist.

Purpose of the Study:

To review key research papers on immune interventions for type 1 diabetes published between July 2009 and June 2010.
To explore studies focusing on preserving beta cell function and interdicting the T1D disease process.
To include relevant articles on the mechanisms, markers, triggers, and pathology of human type 1 diabetes.

Main Methods:

Review of published scientific literature focusing on human studies.
Inclusion of all immune intervention studies reported within the specified timeframe.
Selection of additional articles on T1D mechanisms, markers, triggers, and pathology.

Main Results:

The review covers immune intervention studies aimed at altering the immune system to halt or slow T1D progression.
Selected articles discuss the complex immune mechanisms, including the roles of various immune cells and their interactions.
Evidence suggests that some degree of persistent beta cell function can be observed even in long-standing T1D.

Conclusions:

Preserving beta cell function is a major goal in T1D research, aiming for better glycemic control and reduced complications.
Immune intervention strategies are being investigated for both the evolving stages and the onset of T1D.
Understanding the underlying mechanisms and pathology is crucial for developing effective treatments for type 1 diabetes.